Patrick Wood
Stock Analyst at Morgan Stanley
(2.17)
# 2,864
Out of 5,182 analysts
121
Total ratings
43.75%
Success rate
-2.59%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Equal-Weight | $23 → $25 | $19.82 | +26.14% | 7 | Mar 2, 2026 | |
| MDLN Medline | Maintains: Overweight | $48 → $52 | $45.23 | +14.97% | 2 | Mar 2, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $80 → $85 | $70.48 | +20.60% | 9 | Feb 5, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $130 → $118 | $59.95 | +96.83% | 8 | Feb 5, 2026 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $76 → $83 | $64.34 | +29.00% | 7 | Dec 8, 2025 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $123 → $135 | $108.12 | +24.86% | 3 | Dec 2, 2025 | |
| RXST RxSight | Maintains: Equal-Weight | $9 → $10 | $7.29 | +37.17% | 3 | Dec 2, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $56 → $51 | $24.09 | +111.71% | 4 | Dec 2, 2025 | |
| DXCM DexCom | Upgrades: Overweight | $63 → $75 | $61.41 | +22.13% | 10 | Dec 2, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $197 → $210 | $150.22 | +39.79% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $19 → $15 | $18.49 | -18.88% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $14 → $21 | $15.88 | +32.24% | 9 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $84 → $80 | $76.01 | +5.25% | 5 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $276 → $295 | $222.19 | +32.77% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $81 | $83.46 | -2.95% | 9 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $80 → $103 | $69.78 | +47.61% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $110 → $72 | $122.07 | -41.02% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $191 → $173 | $135.07 | +28.08% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $188.31 | +68.34% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $26.68 | +38.68% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $150.05 | - | 5 | Dec 11, 2017 |
Tandem Diabetes Care
Mar 2, 2026
Maintains: Equal-Weight
Price Target: $23 → $25
Current: $19.82
Upside: +26.14%
Medline
Mar 2, 2026
Maintains: Overweight
Price Target: $48 → $52
Current: $45.23
Upside: +14.97%
GE HealthCare Technologies
Feb 5, 2026
Maintains: Equal-Weight
Price Target: $80 → $85
Current: $70.48
Upside: +20.60%
Boston Scientific
Feb 5, 2026
Maintains: Overweight
Price Target: $130 → $118
Current: $59.95
Upside: +96.83%
The Cooper Companies
Dec 8, 2025
Maintains: Equal-Weight
Price Target: $76 → $83
Current: $64.34
Upside: +29.00%
TransMedics Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $123 → $135
Current: $108.12
Upside: +24.86%
RxSight
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $7.29
Upside: +37.17%
PROCEPT BioRobotics
Dec 2, 2025
Maintains: Overweight
Price Target: $56 → $51
Current: $24.09
Upside: +111.71%
DexCom
Dec 2, 2025
Upgrades: Overweight
Price Target: $63 → $75
Current: $61.41
Upside: +22.13%
Becton, Dickinson and Company
Dec 2, 2025
Maintains: Overweight
Price Target: $197 → $210
Current: $150.22
Upside: +39.79%
Dec 2, 2025
Maintains: Underweight
Price Target: $19 → $15
Current: $18.49
Upside: -18.88%
Dec 2, 2025
Upgrades: Overweight
Price Target: $14 → $21
Current: $15.88
Upside: +32.24%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $84 → $80
Current: $76.01
Upside: +5.25%
Aug 8, 2025
Maintains: Overweight
Price Target: $276 → $295
Current: $222.19
Upside: +32.77%
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $75 → $81
Current: $83.46
Upside: -2.95%
Jul 15, 2025
Upgrades: Overweight
Price Target: $80 → $103
Current: $69.78
Upside: +47.61%
May 6, 2025
Maintains: Underweight
Price Target: $110 → $72
Current: $122.07
Upside: -41.02%
May 5, 2025
Maintains: Overweight
Price Target: $191 → $173
Current: $135.07
Upside: +28.08%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $188.31
Upside: +68.34%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $26.68
Upside: +38.68%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $150.05
Upside: -